News

U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care

U.S. News & World Report has ranked Fox Chase Cancer Center among the nation’s top hospitals for cancer care according to the publication’s 2026-27 Best Hospitals rankings.

News

It Takes a Community for a Winn Scholar to Build a Clinical Trial

“My past experiences with Teach for America in North Philadelphia were a prologue to what I am doing now,” said Austin Williams, MD, MSEd, FACS, a surgical oncologist specializing in breast cancer at Fox Chase Cancer Center and Associate ...

News

Inspiration for Patients and Peers

Meet the Fox Chase physicians and researchers bridging clinical care excellence with breakthroughs in research—bringing new ideas and new hope to peers, patients, and their families.

Course

Young Adult Cancer Symposium:
From Diagnosis Through Survivorship

Date: Wednesday, September 30, 2026 | 5:30 PM - 9:00 PM, Tuesday, October 27, 2026 | 7:00 PM - 9:00 PM

News

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial

This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control ...

News

From Fellowship to Faculty: Building a Fox Chase Career

Arielle Weiss, MD, Assistant Professor, Department of Surgery, and Jason Conger, MD, Assistant Professor, Department of Surgery, both in the Division of Gynecologic Oncology, came to Fox Chase Cancer Center shaped by different experiences, ...

News

From Bench to Bedside to the Block: Dr. Robert A. Winn on Extending Fox Chase's Legacy of Cancer Discovery and Bringing It to the Community

As he begins his tenure at Fox Chase Cancer Center, Dr. Robert Winn brings a national reputation in cancer leadership, discovery, and equitable access - and a vision for science that reaches farther than the clinic.

News

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression ...

News

Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced).